Athenex, inc. announces pricing of $30 million public offering of common stock and warrants

Buffalo, n.y., aug. 11, 2022 (globe newswire) -- athenex, inc. (“athenex”) (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its underwritten public offering of 35,333,334 shares of its common stock and accompanying warrants to purchase up to 35,333,334 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 4,666,666 shares of its common stock and accompanying warrants to purchase up to 4,666,666 shares of common stock at a combined public offering price of $0.749 per share and accompanying warrant . the pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately, and will expire five years following the date of issuance. the warrants have an exercise price of $1.00 per share, are exercisable immediately, and will expire five years following the date of issuance. the gross proceeds to athenex from the offering, before underwriting discounts and commissions and offering expenses, are expected to be approximately $30 million. the offering is expected to close on august 15, 2022, subject to customary closing conditions.
ATNX Ratings Summary
ATNX Quant Ranking